OpenAlex
PricingAboutJobs
Log inGet started
Work

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

HTML

Year: 2019
Type: review
Source: Drug Resistance Updates
DOI: 10.1016/j.drup.2019.100644
Authors: Alessandro Leonetti, Birgit Wever, Giulia Mazzaschi, Yehuda G. Assaraf, Christian Rolfo, Federico Quaini, Marcello Tiseo, Elisa Giovannetti
Institutions: University of Parma, Amsterdam University Medical Centers, Amsterdam UMC Location Vrije Universiteit Amsterdam, Technion – Israel Institute of Technology, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Ospedale di Parma, University of Pisa
Language: English

Topic: Cancer Immunotherapy and Biomarkers
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: non-small cell lung cancer, immune checkpoint inhibitors, chemoimmunotherapy, pembrolizumab, atezolizumab, cancer immunoediting, immunogenic cell death, tumor microenvironment, platinum salts, anthracyclines, patient selection, first-line therapy
SDG: Good health and well-being

Open Access status: closed

Funders: KWF Kankerbestrijding, Associazione Italiana per la Ricerca sul Cancro, Kärntner Wirtschaftsförderungsfonds
Award: G3989004436
OpenAlex ID: W2973445191
FWCI: 2.859
Cites: 129
Cited by: 212
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms